introduction | azacillon is a potent, highly selective, safe, and low-side-effect 5-HT3 receptor antagonist, which is used to prevent and treat nausea and vomiting caused by tumor chemotherapy, radiotherapy and surgery. The characteristic of this drug is not only can effectively inhibit acute nausea and vomiting, but also has a better effect on delayed nausea and vomiting. The synthesis of Azasilon is mainly based on methyl 5-chloro-2-hydroxybenzoate as the starting material, which is nitrated, condensed and cyclized with chloroacetyl chloride, and then methylated, hydrolyzed, chlorinated, aminated and salted to produce products. |
action characteristics | this product is an antiemetics of serotonin type 3 (5-HT3) receptor antagonist. It has a potent and selective antagonistic effect of 5-HT3 receptor, but no dopamine receptor antagonism. This product has a high affinity with 5-HT3 receptors, and its action intensity is about 410 times stronger than metoclopramide (Metoclopramide), which is 2 times higher than ondansetron (On-dansetron), and is almost the same as granisetron (Granisetron). |
use | antiemetic medicine. It is a selective and potent 5-HT3 receptor antagonist with weak or no affinity for other receptors. Used as an antineoplastic agent |
Production method | Methyl 5-chloro-2-hydroxybenzoate (I) is nitrified with nitric acid in sulfuric acid solution to generate nitrate (II), and then reduced to amine (11I) with iron powder and ammonium chloride in water. Then, with chloroacetyl chloride, under the action of sodium bicarbonate, it is acylated and cyclized in the chloroform-water mixture to form a compound (1V). (IV) Methylation with methyl iodide to compound (V) in the presence of potassium carbonate in dimethylformamide. Then hydrolyzed to carboxylic acid (VI), refluxed with thionyl chloride to generate acyl chloride (VII), and finally condensed with 3-aminoquinine in chloroform containing N-methylmorpholine (MML), that is, Azasetron. |